This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
But another experimental monoclonal antibody—ivonescimab—has created ripples in the field of oncology research, by beating the blockbuster medicine pembrolizumab in the third phase of a head-to-head clinical trial (one in …
